Indeed, the combined beneficial effects of SGLT2 inhibitors and GLP-1 receptor agonists on metabolic indices and vascular complications need further investigations for further establishment of this combination in the treatment of T1DM patients. Here, SLC5A2 is linked to type 1 diabetes mellitus.